136 results about "Glycin" patented technology

The present invention provides progastrin-binding molecules specific for progastrin that do not bind gastrin-17(G17), gastrin-34(G34), glycine-extended gastrin-17(G17-Gly), or glycine-extended gastrin-34(G34-Gly). Further, the invention provides monoclonal antibodies (MAbs) selective for sequences at the N-terminus and the C-terminus of the gastrin precursor molecule, progastrin and the hybridomas that produce these MAbs. Also provided are panels of Mabs useful for the detection and quantitation of progastrin and gastrin hormone species in immuno-detection and quantitation assays. These assays are useful for diagnosing and monitoring a gastrin-promoted disease or condition, or for monitoring the progress of a course of therapy. The invention further provides solid phase assays including immunohistochemical (IHC) and immunofluorescence (IF) assays suitable for detection and visualization of gastrin species in solid samples, such as biopsy samples or tissue slices. The progastrin-binding molecules are useful therapeutically for passive immunization against progastrin in progastrin-promoted diseases or conditions. Also provided are surrogate reference standard (SRS) molecules that are peptide chains of from about 10 to about 35 amino acids, wherein the SRS molecule comprises at least two epitopes found in a protein of interest of greater than about 50 amino acids. Such SRS molecules are useful as standards in place of authentic proteins of interest.

The invention belongs to the field of medicine, and relates to a preparation method of a veterinary drug praziquantel, in particular to a novel method for preparing praziquantel. Raw materials such as chloracetyl chloride and glycin used in the method are low in cost and easy to obtain; the reaction is conventional; the operation is simple; the method has no special requirements on equipment; one step that a key intermediate 14 is subjected to intramolecular cyclization to form a compound 15 is designed in a reaction route; the design is brand-new and is not reported previously; the reaction yield is higher in the whole route; the total yield can reach 50%; most solvents used in a reaction process can be recovered, so that the cost is saved, and the environmental pressure is reduced; the cost is lowered extremely; and the route has a very good industrial application prospect.

The invention discloses a method for preparing calcium glycine, which comprises the following steps: respectively taking 15 to 30 weight percent of glycin, 0.8 to 15 weight percent of mineral calcium and 60 to 80 weight percent of water, mixing and stirring the raw materials in a reaction kettle to make the raw materials fully dissolved, performing reaction for 3 to 24 hours by heating at a temperature between 30 and 80 DEG C, and then standing for 6 to 24 hours; taking reaction solution, and performing spray drying or freeze drying to obtain a dry substance; and crushing the dry substance, passing through a 80 to 120-mesh sieve, performing sterilizing and split charging. The method for preparing the calcium glycine has easily obtained raw material used, scientific and reasonable mixture ratio of the raw materials, simple preparation process, high yield of the synthesized calcium glycine, low cost and suitability for industrial production.

The invention relates to a type of Glucagon-likepeptide1 and the use thereof. The structure of the Glucagon-likepeptide1 derivatives is presented in the following formula. The invention also provides a medical salt, a solvolyte, a chelate or a non-covalent complex formed by the compounds shown by the structure, a prodrug based on the compound, or any mix of the above form. The chemical property of the compounds provided in the invention is stable, unlikely to be degraded by IV (DPP-IV) in body. When used for decreasing blood glucose concentration in body, the compound or the drug adopting the compound as an active ingredient have relatively long plasma half-life (above 30 hours) and an significant effect in decreasing blood glucose concentration. X, in the formula, is selected from glycin or glycinamide.